SIRT5 acts in the tumor microenvironment via endothelial cell metabolism to support breast cancer growth
. These results suggest that targeting SIRT5 offers a potential therapeutic strategy to disrupt tumor angiogenesis and suppress TNBC progression by targeting the metabolic vulnerabilities of the tumor endothelium.
Authors
- Hening Lin (ORCID: https://orcid.org/0000-0002-0255-2701)
- Esak Lee (ORCID: https://orcid.org/0000-0002-5328-6677)
- Irma Fernández (ORCID: https://orcid.org/0000-0003-0063-4612)
- Zeribe C. Nwosu (ORCID: https://orcid.org/0000-0003-1641-2045)
- Joeva J. Barrow
- Pei-Yin Tsai (ORCID: https://orcid.org/0000-0001-7132-5986)
- Issahy Cano (ORCID: https://orcid.org/0000-0001-9994-149X)
- Sadhan Jana (ORCID: https://orcid.org/0000-0002-7736-0560)
- Rita Weiss
- Qian Zhao
- Elijah Bacchus
- Anthony Max Chen (ORCID: https://orcid.org/0000-0003-0753-8607)
- Andrew D. Miller
Institutions
- Cornell University (US)
- University of Chicago (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-04-13
- DOI
- https://doi.org/10.64898/2026.04.09.717584
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health